AstraZeneca has a deep-rooted heritage in the Oncology therapeutic area. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and haematological cancers. These are being targeted through four key platforms – immuno-oncology, genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.
- Booth Number: 2
Bristol-Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb company and Juno Therapeutics, a Bristol-Myers Squibb company.
- Booth Number: 3
F. Hoffmann-La Roche Ltd
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
- Booth Number: 12
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world.
- Booth Number: 13
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.
- Booth Number: 14
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
- Booth Number: 10a
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company’s approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.
- Booth Number: 2
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit:
- No booth
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.
- Booth Number: 16
Takeda Pharmaceuticals International AG
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
- Booth Number: 11b
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies – with a primary focus on novel oncology treatments – to improve standards of care and address unmet medical needs globally by leveraging our world-class science and technology. Daiichi Sankyo´s 15´000 employees worldwide draw upon a rich legacy of innovation and a robust pipeline of promising medicines.
- Booth Number: 10b
Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Molecular Health is a data science-focused artificial intelligence computing company dedicated to big-data capture, curation, integration and analytics to enable precision medicine and generate novel and actionable insights on drug outcomes for stakeholders across the healthcare ecosystem.
- Booth Number: 10c
Thermo Fisher Scientific
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision oncology progress and implementation through innovative technologies and service. We offer a suite of next generation sequencing tests for genomic profiling of solid and hematological tumors including liquid biopsy and immuno-oncology applications.
- Booth Number: 15